SBRT in stage III NSCLC / Non Small Cell Lung Cancer · Interventional Study

The APRIL Trial Evaluating Upfront Stereotactic Body Radiotherapy in Stage III Advanced Non-small Cell Lung Cancer

ClinicalTrials.gov · September 11, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a prospective interventional feasibility study of stereotactic body radiotherapy combined with chemotherapy for stage III non-small cell lung cancer, currently not yet recruiting. No results have been posted in this registry record, so no efficacy or safety data are available to judge.

What was studied

Interventional, Single Group, Open label, Treatment purpose. Non Small Cell Lung Cancer; age from 18 Years; to 75 Years; accepts healthy volunteers. Intervention: SBRT in stage III NSCLC. n = 20. 1 site: India.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a registry record for a planned feasibility study with no results posted; it describes an unstarted interventional trial in an understudied population and endpoint.

Study design

As stated by the source record.

MethodsPrimary outcome measure: Loco-regional control rate (assessed at 2 years)

DesignInterventional, Single Group, Open label, Treatment purpose

PopulationNon Small Cell Lung Cancer; age from 18 Years; to 75 Years; accepts healthy volunteers

Sample size20

InterventionSBRT in stage III NSCLC

Setting1 site: India

Reported figures

Quoted from the source exactly as published.

Planned enrollment20

Primary outcome measureLoco-regional control rate at 2 years

Target tumour/lymph node size≤6 cm

Caveats

This is a registry record only; no results are reported.
Study has not yet begun recruitment (status: NOT_YET_RECRUITING).
No phase designation provided; study design details (randomization, blinding, control arm) are not described.
Sample size of 20 is very small and limits generalizability and power for clinical decision-making.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

limited

Interventional feasibility study; phase not specified; no control arm described.

Directness

moderate

Primary outcome is loco-regional control rate at 2 years in stage III NSCLC.

Consistency

insufficient

Registry record contains no results; consistency cannot be assessed.

Risk of bias

insufficient

No methods, randomization, or blinding described in this registry record.

Sample adequacy

limited

Planned enrollment 20 participants; very small sample for a definitive outcome.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07565987). This is a study registration, not published results. Lead sponsor: All India Institute of Medical Sciences. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Non Small Cell Lung Cancer. Interventions: RADIATION: SBRT in stage III NSCLC. Primary outcome measures: Loco-regional control rate , 2 years. Brief summary: The aim of the study is to test the feasibility \& loco-regional control rate by combining high precision SBRT with chemotherapy in stage III NSCLC in tumor/lymph nodes if tumors/lymph node size with ≤ 6cms in size.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT07565987SBRT in stage III NSCLCAll India Institute of Medical SciencesNon Small Cell Lung Cancer